The Oncology Institute is rebranding its clinical research division. Previously, TOI‘s clinical research division was named Innovative Clinical Research Institute. The division’s new name is TOI Clinical Research. TOI Clinical Research will carry on the important work ICRI has been conducting since its founding in 2011. TOI Clinical Research currently manages over 160 clinical trials across solid tumors and hematological malignancies. TOI Clinical Research will follow the same successful model that helped build ICRI into a leader in the field of cancer clinical trials, relying on a network of compassionate, experienced cancer care specialists dedicated to providing clinical trials as a treatment option. As TOI Clinical Research grows in 2023, there will be a continued commitment to streamlined screening of TOI patients for eligibility for appropriate trials, expanding access at more sites across the country, and improving health equity by offering these treatments in underserved and diverse communities.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TOI:
- The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto Ochoa
- Credit Suisse to hold a conference
- The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance
- The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare Conference
- The Oncology Institute Executives to Speak at Key Industry Conferences in Q4
